These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 19189306)
1. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Palapattu GS; Wu C; Silvers CR; Martin HB; Williams K; Salamone L; Bushnell T; Huang LS; Yang Q; Huang J Prostate; 2009 May; 69(7):787-98. PubMed ID: 19189306 [TBL] [Abstract][Full Text] [Related]
2. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cox ME; Deeble PD; Lakhani S; Parsons SJ Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Huang J; Yao JL; di Sant'Agnese PA; Yang Q; Bourne PA; Na Y Prostate; 2006 Sep; 66(13):1399-406. PubMed ID: 16865726 [TBL] [Abstract][Full Text] [Related]
4. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Dizeyi N; Bjartell A; Nilsson E; Hansson J; Gadaleanu V; Cross N; Abrahamsson PA Prostate; 2004 May; 59(3):328-36. PubMed ID: 15042609 [TBL] [Abstract][Full Text] [Related]
5. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells]. Song Y; Wu G; Xin DQ; Na YQ Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464 [TBL] [Abstract][Full Text] [Related]
6. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361 [TBL] [Abstract][Full Text] [Related]
7. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Harrison GM; Davies G; Martin TA; Mason MD; Jiang WG Oncol Rep; 2006 Jan; 15(1):199-206. PubMed ID: 16328056 [TBL] [Abstract][Full Text] [Related]
8. Secretagogin is a new neuroendocrine marker in the human prostate. Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592 [TBL] [Abstract][Full Text] [Related]
9. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer. Wu C; Zhang L; Bourne PA; Reeder JE; di Sant'Agnese PA; Yao JL; Na Y; Huang J Prostate; 2006 Aug; 66(11):1125-35. PubMed ID: 16652382 [TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Xing N; Qian J; Bostwick D; Bergstralh E; Young CY Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682 [TBL] [Abstract][Full Text] [Related]
11. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone. Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260 [TBL] [Abstract][Full Text] [Related]
12. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Patrawala L; Calhoun-Davis T; Schneider-Broussard R; Tang DG Cancer Res; 2007 Jul; 67(14):6796-805. PubMed ID: 17638891 [TBL] [Abstract][Full Text] [Related]
13. Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Dizeyi N; Bjartell A; Hedlund P; Taskén KA; Gadaleanu V; Abrahamsson PA Eur Urol; 2005 Jun; 47(6):895-900. PubMed ID: 15925089 [TBL] [Abstract][Full Text] [Related]
14. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Tran CP; Lin C; Yamashiro J; Reiter RE Mol Cancer Res; 2002 Dec; 1(2):113-21. PubMed ID: 12496358 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353 [TBL] [Abstract][Full Text] [Related]
16. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia. Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762 [TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine differentiation in human prostatic tumor models. Noordzij MA; van Weerden WM; de Ridder CM; van der Kwast TH; Schröder FH; van Steenbrugge GJ Am J Pathol; 1996 Sep; 149(3):859-71. PubMed ID: 8780390 [TBL] [Abstract][Full Text] [Related]
19. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer]. Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097 [TBL] [Abstract][Full Text] [Related]
20. Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy. Shimizu S; Kumagai J; Eishi Y; Uehara T; Kawakami S; Takizawa T; Koike M Prostate; 2007 May; 67(6):645-52. PubMed ID: 17342745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]